Katherine Wilemon, Family Heart Foundation CEO, receives Honorary Fellow Award from ASPC for her advocacy and research efforts in inherited lipid disorders. The award reflects the organization's impact on advancing care and awareness for conditions like familial hypercholesterolemia.
The Family Heart Foundation, led by Matt Hasselbeck, aims to educate Americans about the risks of high LDL cholesterol and its connection to early heart disease. The campaign promotes free at-home screenings and offers support for individuals to protect themselves and their families from cardiovascular disease.
A recent study published in the American Journal of Preventive Cardiology found that only 13% of US adults with cardiovascular disease met optimal LDL-C management, highlighting significant gaps between guideline recommendations and clinical care. The study suggests actionable steps to improve adherence, including increased use of non-...
The Family Heart Foundation has launched the Lp(a) AW(a)RE initiative to educate primary care clinicians, healthcare insurance providers, and policymakers about high lipoprotein(a). The program aims to increase awareness, screening, and diagnosis of this genetic risk factor for premature cardiovascular disease.
A multidisciplinary panel published in the Journal of Pediatrics advocates for accelerated diagnosis of familial hypercholesterolemia, a life-threatening genetic condition. Universal lipid screening is recommended to identify affected children at high risk of heart disease decades earlier than those without the condition.
The Family Heart Foundation has partnered with seven leading healthcare systems to accelerate screening in people with cardiovascular disease who have been identified by the find Lp(a) initiative. Individuals with elevated Lp(a) levels are at increased risk of another heart attack or stroke, and early detection can help reduce this risk.
A study of 273,770 individuals with cardiovascular disease found that increasing lipoprotein(a) levels significantly increases the risk of subsequent cardiovascular events. Treatment with high-impact LDL-C lowering therapies may help reduce this risk.
Dr. Laurence S. Sperling will lead programs focused on genetic causes of stroke in Americans, aiming to dramatically improve screening and diagnosis rates. The Family Heart Foundation appoints Dr. Sperling as Chief Medical Officer to drive this initiative.
Dr. Seth Baum, a renowned expert in preventive cardiology and lipidology, has been appointed Chairman of the Family Heart Foundation's Board of Directors. He will work to advance the organization's mission-driven initiatives, including increasing awareness for inherited lipid disorders and improving healthcare processes.
A new study reveals that utilization of PCSK9 inhibitors is low among high-risk patients, despite extensive evidence documenting their role in LDL-C reduction and the prevention of heart attacks. The study found that insurance coverage rejection or abandonment leads to significantly more cardiovascular events within 12 months.
A new study reveals delayed diagnosis of HoFH leads to premature cardiovascular disease, highlighting the need for increased lipid screening and aggressive treatment. Despite available therapies, most patients require further lipid-lowering treatments.
A real-world analysis found that high-risk Americans who fail to reach guideline-recommended LDL-C levels experience a 44% higher rate of cardiovascular events. The study, presented at the AMCP Conference, used data from over 300 million Americans and compared those who met and maintained recommended targets with those who did not.
A recent analysis of the Family Heart Database found that individuals with familial hypercholesterolemia are more likely to receive adequate treatment if they are White, male, and have higher income or education. The study highlights a significant unmet need for improving equity in cardiovascular risk reduction.
Children with homozygous familial hypercholesterolemia are diagnosed earlier and have higher untreated LDL-C levels than adults, while those not identified early miss out on decades of life-saving treatment. This study emphasizes the need for universal screening to identify children with HoFH or heterozygous familial hypercholesterolemia.
A new analysis from the Family Heart Foundation shows that only 31.3% of individuals with familial hypercholesterolemia (FH) in its database had been diagnosed as of June 2020. This represents a significant increase since 2016, but highlights the ongoing challenge of diagnosing and managing the condition.
A new study by the Family Heart Foundation found that COVID-19 increases heart attack rates in individuals with familial hypercholesterolemia and established atherosclerotic cardiovascular disease. The study analyzed data from 55 million individuals and confirmed that COVID-19 worsens cardiovascular outcomes.
New data from the CASCADE FH Registry highlights gaps in care for children with familial hypercholesterolemia. Children are typically diagnosed at age 9, seven years after cholesterol screening guidelines recommend it. Early treatment intervention can prevent cardiovascular disease.
A global coalition is calling for early screening and coordinated lifetime care for familial hypercholesterolemia, a condition affecting 34 million people worldwide. The initiative aims to prevent premature cardiovascular disease and save lives by leveraging scientific data, novel therapies, and technological advances.
A new machine learning algorithm identified individuals with probable familial hypercholesterolemia (FH) for the first time at a national scale, reducing the number of people needed to be screened. The FIND FH model performed comparably well on diverse healthcare data and has been implemented in several US healthcare systems.
Individuals with familial hypercholesterolemia face a high risk of heart attack and stroke despite receiving multiple cholesterol-lowering treatments. The study found that only 52% of adults with FH meet LDL-cholesterol targets, highlighting the need for more aggressive treatment.
A new study found that individuals with familial hypercholesterolemia (FH) or atherosclerotic heart disease (ASCVD) experienced more cardiovascular events when they couldn't get their prescribed LDL-cholesterol lowering medication. Those whose PCSK9 inhibitors were rejected by insurance had a 16% increased risk of a cardiovascular even...